within Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AG01_Fluspirilene;

model Fluspirilene
  extends Pharmacolibrary.Drugs.ATC.N.N05AG01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N05AG01</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fluspirilene is a diphenylbutylpiperidine antipsychotic medication primarily used in the long-term management of schizophrenia. It is a long-acting typical (first-generation) neuroleptic, mainly administered as a depot intramuscular injection, and is not widely approved or available in all countries today.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for fluspirilene in adults, as precise clinical PK data are not widely published; values are derived from secondary summaries and review articles of clinical use.</p><h4>References</h4><ol><li><p>Spanarello, S, &amp; La Ferla, T (2014). The pharmacokinetics of long-acting antipsychotic medications. <i>Current clinical pharmacology</i> 9(3) 310–317. DOI:<a href=&quot;https://doi.org/10.2174/15748847113089990051&quot;>10.2174/15748847113089990051</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23343447/&quot;>https://pubmed.ncbi.nlm.nih.gov/23343447</a></p></li><li><p>Altamura, AC, et al., &amp; Mundo, E (2003). Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. <i>Drugs</i> 63(5) 493–512. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363050-00004&quot;>10.2165/00003495-200363050-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12600227/&quot;>https://pubmed.ncbi.nlm.nih.gov/12600227</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fluspirilene;
